Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy

PHASE2RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 10, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Paraneoplastic Sensory Neuronopathy
Interventions
DRUG

Immunoglobulins IV (CLAYRIG)

"Patients will be treated with cycles of :~\- Intravenous (IV) immunoglobulins: 2 g/kg per cycle, over 3 to 5 days (D1 to D3 or D5).~Cycles will be administered every 4 weeks for a total of 3 first cycles"

DRUG

Cyclophosphamide IV

"Patients will be treated with cycles of :~\- Cyclophosphamide IV: 1 g on the first day (D1). Cycles will be administered every 4 weeks for a total of 6 cycles"

DRUG

Methylprednisolone IV

"Patients will be treated with cycles of :~Methylprednisolone IV: 1 g/day for 3 days (D1 to D3). Cycles will be administered every 4 weeks for a total of 6 cycles"

Trial Locations (1)

75013

RECRUITING

Hôpital Pitié-Salpêtrière, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER